|Dr. Robert James Wills B.S., M.S., Ph.D.||Chairman||61k||N/A||1954|
|Mr. Sujal A. Shah||Pres, CEO & Director||726.33k||N/A||1973|
|Mr. Daniel Menold||VP of Fin.||352.39k||40k||1970|
|Dr. Charles A. McWherter||Sr. VP & Chief Scientific Officer||580.43k||N/A||1955|
|Mr. Paul T. Quinlan||Gen. Counsel & Corp. Sec.||537.91k||N/A||1963|
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, a selective orally-active G protein-coupled receptor agonist that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion for the treatment of gut/liver disease. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has development and licensing agreement with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders; and a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comrprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
CymaBay Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2019 is 7. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 6; Compensation: 9.